New Positions Created to Manage Dramatic Growth
HORSHAM, Pa.; May 4, 2021 – Clinical Ink, a global clinical trial technology company, today announced the hiring of CCO Chris Crucitti, COO Brian Donahue, and VP Project Operations Bill Barrasso. All three positions are newly created to help manage the unprecedented industry demand for the eSource leader’s eCOA, ePRO+, DDC, and eConsent platform.
“Clinical Ink pioneered the development of decentralized trials (eSource) long before the label even existed and we are responding to the tremendous growth opportunities ahead,” said Clinical Ink CEO, Ed Seguine. “This industry is plagued with visionary talk that so often lacks substance and comes up short in real-life. Adding these experienced industry veterans builds on the disciplined execution mindset we have cultivated over the years. These leaders bring great insight, expertise, and vision to our confident, reliable delivery of results in the most complex and demanding therapeutic areas.”
Clinical Ink’s Lunexis platform collects clinical trial data from patients and clinicians, at home and on-site. In the past three years, project bookings have tripled, revenue more than quadrupled, and backlog has grown by 500%. Clinical Ink has conducted hundreds of clinical trials on the Lunexis decentralized trial platform, capturing data from patients where they live — everywhere from villages in West Africa, mountaintops in Nepal, nursing homes in Europe, and patient homes in 60+ countries. Lunexis began as a way to transition sites from EDC to DDC (eSource) and to enable easier patient participation at home with BYOD ePRO+. It now offers “Build Your Own Study” capabilities for sponsors and CROs to have greater control over study design and execution.
Chris Crucitti, Chief Commercial Officer
Christopher L. Crucitti is a 20+ year life sciences and clinical services/technology executive. Prior to joining Clinical Ink, Chris most recently held the role of Chief Commercial Officer at Signant Health, where he led the commercial functions and go-to-market strategy. In addition, Chris brings significant experience and expertise in the clinical and R&D domains, including full-service CRO, data and analytics, eClinical technology solutions, strategic resourcing, and consulting.
“I am very excited to join Clinical Ink’s team of incredibly smart, passionate, and committed problem-solvers,” said Crucitti. “My primary goals are to solidify Clinical Ink’s customer-focused approach as we continue our rapid growth, to optimize an already high performing go-to-market strategy, and to build a trusted expertise-based partnership model with our customers. We will also continue to innovate, while demonstrating thought-leadership, to meet the critical goals and challenges of our customers in a quickly evolving clinical development landscape. Clinical Ink has quietly been involved in some of the most consequential clinical programs over the past several years and I look forward to the many opportunities to expedite the process of delivering meaningful treatments to the patients who need them.”
Brian Donahue, Chief Operating Officer
Prior to joining Clinical Ink, Brian held a variety of leadership roles at GE for 16 years. Brian started his career in GE’s world-renowned Operations Leadership Program. This led to multiple roles within GE Capital prior to his transition to GE Healthcare, where he served in multiple operational, commercial, and general management leadership positions in the U.S. and Canada.
“Leading Clinical Ink through its next phase of growth will require expanded operations functions with an emphasis on superior customer support across the organization,” said Donahue. “The ongoing support of our customer base and enhanced data reporting will be integral to customer satisfaction and retention, and I look forward to developing our strategy for shared services, project management, and operations functions across the business.”
Bill Barrasso, Vice President, Project Operations
Bill Barrasso brings a deep understanding of clinical trial processes and regulatory guidance required for successful study execution. Bill established the eCOA delivery services team at Parexel after leading eCOA services organizations at both ERT and PHT Corporation. Prior to that, he was the Director of Operations at Concordant Rater Systems (rater monitoring and eCOA data collection in CNS studies), which was acquired by United BioSource Corporation and spun off into Bracket.
“Global delivery processes, excellence in execution, and operational strategies for the delivery services organization will ensure Clinical Ink remains at the forefront of the eCOA/eSource/ Decentralized Trial transformation,” said Barrasso. “I look forward to driving study management processes that deliver high-quality and timely solutions to our valued clients.”
About Clinical Ink
Clinical Ink, a global clinical technology company, offers data certainty from source to submission via our Lunexis eSource clinical technology and configurable direct data capture, eCOA, ePRO+, and eConsent modules. This suite of solutions for capturing and integrating electronic data from sites, clinicians, patients, and caregivers at its source naturally enhances clinical trial workflows. For virtual, traditional, or hybrid trials, Lunexis technology reduces manual labor and associated delays, and provides anytime, anywhere data access, saving resources as your trials progress. For more information, visit clinicalink.com.